News about Regulation

Dr. Reddy's Wins European Approval for Denosumab Biosimilar

Dr. Reddy's Wins European Approval for Denosumab Biosimilar

Dr. Reddy’s Laboratories has received approval from the European Commission for its denosumab biosimilar, used in the treatment of osteoporosis and cancer-related bone conditions.

Regulation | 25/11/2025 | By Darshana

Ocuvex Resubmits CRL to FDA for PDP-716 NDA, SPARC Reveals

Ocuvex Resubmits CRL to FDA for PDP-716 NDA, SPARC Reveals

Sun Pharma Advanced Research Company (SPARC) announced that Ocuvex Therapeutics has resubmitted a Complete Response Letter (CRL) to the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of PDP-716.

Regulation | 20/11/2025 | By Dineshwori 115

Biocon Pharma Receives US FDA Nod for Tofacitinib Extended-Release Tablets

Biocon Pharma Receives US FDA Nod for Tofacitinib Extended-Release Tablets

Biocon Pharma has received approval from the US Food and Drug Administration (US FDA) for its ANDA for tofacitinib extended-release tablets, securing final approval for the 11 mg strength and tentative approval for the 22 mg strength.

Regulation | 19/11/2025 | By Dineshwori 111

Lilly India Receives CDSCO Approval for Donanemab to Treat Early Alzheimer's Disease

Lilly India Receives CDSCO Approval for Donanemab to Treat Early Alzheimer's Disease

Eli Lilly and Company (India) Pvt. Ltd. has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for donanemab, a treatment for adults in the early symptomatic stages of Alzheimer’s disease.

Regulation | 18/11/2025 | By Darshana 136

EMA Enhances Scientific Advice Process for Medicines Targeting Public Health Threats

EMA Enhances Scientific Advice Process for Medicines Targeting Public Health Threats

Under the new system, medicine developers can receive joint scientific advice from EMA and national clinical and ethics experts. This coordinated approach aligns trial and regulatory requirements early, helping accelerate trial approvals and access to critical medicines.

Regulation | 18/11/2025 | By Dineshwori 202

Zydus Lifesciences Secures US FDA Approval for Leuprolide Acetate Injection

Zydus Lifesciences Secures US FDA Approval for Leuprolide Acetate Injection

Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for its generic version of Leuprolide Acetate injection, in a 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial format.

Regulation | 17/11/2025 | By Darshana 111

IPC and Jharkhand Pharmacy Council Join Hands to Strengthen Drug Safety

IPC and Jharkhand Pharmacy Council Join Hands to Strengthen Drug Safety

The Indian Pharmacopoeia Commission (IPC) and the Jharkhand State Pharmacy Council (JSPC) have signed an MoU to improve medication safety and strengthen pharmacovigilance across the state.

Regulation | 16/11/2025 | By Darshana 105

CHMP Recommends Sanofi's Tezeild for EU Approval in Stage 2 Type 1 Diabetes

CHMP Recommends Sanofi's Tezeild for EU Approval in Stage 2 Type 1 Diabetes

The CHMP has backed EU approval for Sanofi’s Tezeild, supported by TN-10 study results showing the therapy can delay progression to stage 3 type 1 diabetes in patients with stage 2 disease. If authorised, Tezeild would become the first disease-modifying treatment for T1D in the EU.

Regulation | 15/11/2025 | By Dineshwori 190

Alembic Pharmaceuticals Secures Multiple USFDA Approvals; Q2 Revenue Rises 16 Percent

Alembic Pharmaceuticals Secures Multiple USFDA Approvals; Q2 Revenue Rises 16 Percent

Alembic Pharmaceuticals has announced a series of regulatory milestones, receiving final approval from the US Food & Drug Administration (USFDA) for four Abbreviated New Drug Applications (ANDAs) in the month.

Regulation | 15/11/2025 | By Dineshwori

Zydus Lifesciences Receives USFDA Tentative Nod for Generic Multiple Sclerosis Drug

Zydus Lifesciences Receives USFDA Tentative Nod for Generic Multiple Sclerosis Drug

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Diroximel Fumarate delayed-release capsules, 231 mg, a generic version of Vumerity delayed-release capsules of the same strength.

Regulation | 13/11/2025 | By Dineshwori 226

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members